Pfizer Submits Initial Data for COVID-19 Vaccine Booster Authorization

August 18, 2021

(Medscape) – Pfizer Inc and its German partner BioNTech SE have submitted to U.S. regulators the initial data from an early-stage trial toward seeking authorization of a booster dose of their COVID-19 vaccine, the drugmakers said on Monday. They said the third dose produced “significantly higher” neutralizing antibodies against the original, wild-type SARS-CoV-2 virus compared to the initial two doses, as well as against the Beta and the highly infectious Delta variants. (Read Full Article)